Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David W. Lowrance is active.

Publication


Featured researches published by David W. Lowrance.


PLOS Medicine | 2009

Task shifting for scale-up of HIV care: Evaluation of nurse-centered antiretroviral treatment at Rural Health Centers in Rwanda

Fabienne Shumbusho; Johan van Griensven; David W. Lowrance; Innocent Turate; Mark A. Weaver; Jessica Price; Agnes Binagwaho

Fabienne Shumbusho and colleagues evaluate a task-shifting model of nurse-centered antiretroviral treatment prescribing in rural primary health centers in Rwanda and find that nurses can effectively and safely prescribe ART when given adequate training, mentoring, and support.


Journal of Acquired Immune Deficiency Syndromes | 2009

Adult Clinical and Immunologic Outcomes of the National Antiretroviral Treatment Program in Rwanda During 2004-2005

David W. Lowrance; Francois Ndamage; Eugenie Kayirangwa; Felix Ndagije; Wilson Lo; Donald R. Hoover; Jeff Hanson; Batya Elul; Aliou Ayaba; Tedd V. Ellerbrock; Alphonse Rukundo; Fabienne Shumbusho; Denis Nash; Jules Mugabo; Anita Assimwe

Background:By December 2007, over 48,000 persons had initiated antiretroviral treatment (ART) at 171 clinics in Rwanda. Assessing national ART program outcomes is essential to determine whether programs have the desired impact. Methods:We conducted a retrospective cohort study to assess key 6- and 12-month outcomes among a nationally representative, stratified, random sample of 3194 adults (≥15 years) who initiated ART from January 1, 2004, through December 31, 2005. Findings:At ART initiation, the median patient age was 37 years and 65% were female. Overall, the baseline median CD4+ cell count was 141 cells per microliter. At 6 and 12 months after ART initiation, 92% and 86% of patients, respectively, remained on ART at their original site. By 6 months, 3.6% were dead and 3.4% were lost to follow-up; by 12 months, 4.6% were dead and 4.9% were lost to follow-up. Among patients with available follow-up CD4+ cell count data, median CD4+ cell counts increased by 98 cells per microliter and 119 cells per microliter at 6 and 12 months after ART initiation, respectively. Conclusions:Rwandas national ART program achieved excellent 6- and 12-month retention and immunologic outcomes during the first 2 years of rapid scale-up. Routine supervision is required to improve compliance with clinical guidelines and data quality.


Journal of Acquired Immune Deficiency Syndromes | 2008

A public health approach to rapid scale-up of antiretroviral treatment in Malawi during 2004-2006.

David W. Lowrance; Simon D. Makombe; Anthony D. Harries; Ray W. Shiraishi; Mindy Hochgesang; John Aberle-Grasse; Edwin Libamba; Erik J Schouten; Tedd V. Ellerbrock; Kelita Kamoto

Background:Approximately 1 million people are infected with HIV in Malawi, where AIDS is the leading cause of death in adults. By December 31, 2007, more than 141,000 patients were initiated on antiretroviral treatment (ART) by use of a public health approach to scale up HIV services. Methods:We analyzed national quarterly and longitudinal cohort data from October 2004 to December 2006 to examine trends in characteristics of patients initiating ART, end-of-quarter clinical outcomes, and 6- and 12-month survival probability. Findings:During a 27-month period, 72,666 patients were initiated on ART, of whom about two-thirds were women. The percentage of patients initiated on ART who were children and farmers increased from 5.5% to 9.0% and 23% to 32%, respectively (P < 0.001 for trends). Estimated survival probability ranged from 85% to 88% at 6 months and 81% to 84% at 12 months on ART. Interpretation:In Malawi, a public health approach to ART increased treatment access and maintained high 6- and 12-month survival. Resource-limited countries scaling up ART programs may benefit from this approach of simplified clinical decision making, standardized ART regimens, nonphysician care, limited laboratory support, and centralized monitoring and evaluation.


Journal of Acquired Immune Deficiency Syndromes | 2012

Cell phone-based and internet-based monitoring and evaluation of the National Antiretroviral Treatment Program during rapid scale-up in Rwanda: TRACnet 2004-2010.

Sabin Nsanzimana; Hinda Ruton; David W. Lowrance; Shabani Cishahayo; Jean Pierre Nyemazi; Ribakare Muhayimpundu; Corine Karema; Pratima L. Raghunathan; Agnes Binagwaho; David J. Riedel

Background:Monitoring and evaluation of antiretroviral treatment (ART) scale-up has been challenging in resource-limited settings. We describe an innovative cell-phone-based and internet-based reporting system (TRACnet) utilized in Rwanda. Methods:From January 2004 to June 30, 2010, all health facilities with ART services submitted standardized monthly aggregate reports of key indicators. National cohort data were analyzed to examine trends in characteristics of patients initiating ART and cumulative cohort outcomes. Estimates of HIV-infected patients eligible for ART were obtained from Joint United Nations Program on HIV/AIDS (Estimation and Projection Package-Spectrum, 2010). Results:By June 30, 2010, 295 (65%) of 451 health centers, District and referral hospitals provided ART services; of these, 255 (86%) were located outside Kigali, the capital. Cell phone–based and internet-based reporting was used by 253 (86%) and 42 (14%), respectively. As of June 30, 2010, 83,041 patients were alive on ART, 6171 (6%) had died, and 9621 (10%) were lost-to-follow-up. Of those alive on ART, 7111 (8.6%) were children, 50,971 (61.4%) were female, and 1823 (2.2%) were on a second-line regimen. The proportion of all patients initiating ART at World Health Organization clinical stages 3 and 4 declined from 65% in 2005 to 27% in 2010. National ART coverage of eligible patients increased from 13% in 2005 to 79% in 2010. Conclusions:Rwanda has successfully expanded ART access and achieved high national ART coverage among eligible patients. TRACnet captured essential data about the ART program during rapid scale-up. Cell phone-based and internet-based reporting may be useful for monitoring and evaluation of similar public health initiatives in other resource-limited settings.


Tropical Medicine & International Health | 2007

Assessment of a national monitoring and evaluation system for rapid expansion of antiretroviral treatment in Malawi.

David W. Lowrance; Scott Filler; Simon D. Makombe; Anthony D. Harries; John Aberle-Grasse; Mindy Hochgesang; Edwin Libamba

Objectives  Monitoring and evaluation of national antiretroviral therapy (ART) programs is vital, but routine, standardized assessment of national ART patient monitoring systems has not been established. Malawi has undertaken an ambitious ART scale‐up effort, with over 57 000 patients initiated on ART by June 2006. We assessed the national ART monitoring and evaluation system in Malawi to ensure that the response to the epidemic was being monitored efficiently and effectively, and that data collected were useful.


Morbidity and Mortality Weekly Report | 2015

Lower levels of antiretroviral therapy enrollment among men with HIV compared with women - 12 countries, 2002-2013

Andrew F. Auld; Ray W. Shiraishi; Francisco Mbofana; Aleny Couto; Ernest Benny Fetogang; Shenaaz El-Halabi; Refeletswe Lebelonyane; Pilatwe T lhagiso Pilatwe; Ndapewa Hamunime; Velephi Okello; Tsitsi Mutasa-Apollo; Owen Mugurungi; Joseph Murungu; Janet Dzangare; Gideon Kwesigabo; Fred Wabwire-Mangen; Modest Mulenga; Sebastian Hachizovu; Virginie Ettiegne-Traore; Fayama Mohamed; Adebobola Bashorun; Do T hi Nhan; Nguyen H uu Hai; Tran H uu Quang; Joelle Deas Van Onacker; Kesner Francois; Ermane Robin; Gracia Desforges; Mansour Farahani; Harrison Kamiru

Equitable access to antiretroviral therapy (ART) for men and women with human immunodeficiency virus (HIV) infection is a principle endorsed by most countries and funding bodies, including the U.S. Presidents Emergency Plan for AIDS (acquired immunodeficiency syndrome) Relief (PEPFAR) (1). To evaluate gender equity in ART access among adults (defined for this report as persons aged ≥15 years), 765,087 adult ART patient medical records from 12 countries in five geographic regions* were analyzed to estimate the ratio of women to men among new ART enrollees for each calendar year during 2002-2013. This annual ratio was compared with estimates from the Joint United Nations Programme on HIV/AIDS (UNAIDS)(†) of the ratio of HIV-infected adult women to men in the general population. In all 10 African countries and Haiti, the most recent estimates of the ratio of adult women to men among new ART enrollees significantly exceeded the UNAIDS estimates for the female-to-male ratio among HIV-infected adults by 23%-83%. In six African countries and Haiti, the ratio of women to men among new adult ART enrollees increased more sharply over time than the estimated UNAIDS female-to-male ratio among adults with HIV in the general population. Increased ART coverage among men is needed to decrease their morbidity and mortality and to reduce HIV incidence among their sexual partners. Reaching more men with HIV testing and linkage-to-care services and adoption of test-and-treat ART eligibility guidelines (i.e., regular testing of adults, and offering treatment to all infected persons with ART, regardless of CD4 cell test results) could reduce gender inequity in ART coverage.


The Journal of Infectious Diseases | 2012

Influenza Sentinel Surveillance in Rwanda, 2008–2010

Thierry Nyatanyi; Richard Nkunda; Joseph Rukelibuga; Rakhee Palekar; Marie Aimée Muhimpundu; Adeline Kabeja; Alice Kabanda; David W. Lowrance; Stefano Tempia; Jean Baptiste Koama; David McAlister; Odette Mukabayire; Justin Wane; Pratima L. Raghunathan; Mark A. Katz; Corine Karema

BACKGROUND In 2008, Rwanda established an influenza sentinel surveillance (ISS) system to describe the epidemiology of influenza and monitor for the emergence of novel influenza A viruses. We report surveillance results from August 2008 to July 2010. METHODS We conducted ISS by monitoring patients with influenza-like illness (ILI) and severe acute respiratory infection (SARI) at 6 hospitals. For each case, demographic and clinical data, 1 nasopharyngeal specimen, and 1 oropharyngeal specimen were collected. Specimens were tested by real-time reverse-transcription polymerase chain reaction for influenza A and B viruses at the National Reference Laboratory in Rwanda. RESULTS A total of 1916 cases (945 ILI and 971 SARI) were identified. Of these, 29.2% (n = 276) of ILI and 10.4% (n = 101) of SARI cases tested positive for influenza. Of the total influenza-positive cases (n = 377), 71.8% (n = 271) were A(H1N1) pdm09, 5.6% (n = 21) influenza A(H1), 7.7% (n = 29) influenza A(H3), 1.6% (n = 6) influenza A (unsubtyped), and 13.3% (n = 50) influenza B. The percentage of positivity for influenza viruses was highest in October-November and February-March, during peaks in rainfall. CONCLUSIONS The implementation of ISS enabled characterization of the epidemiology and seasonality of influenza in Rwanda for the first time. Future efforts should determine the population-based influenza burden to inform interventions such as targeted vaccination.


Journal of Clinical Microbiology | 2014

Limited Utility of Dried-Blood- and Plasma Spot-Based Screening for Antiretroviral Treatment Failure with Cobas Ampliprep/TaqMan HIV-1 Version 2.0

Souleymane Sawadogo; Andreas Shiningavamwe; Joy Chang; Andrew D. Maher; Guoqing Zhang; Chunfu Yang; Esegiel Gaeb; Harold Kaura; Dennis Ellenberger; David W. Lowrance

ABSTRACT The 2013 WHO antiretroviral therapy (ART) guidelines recommend dried blood spots (DBS) as an alternative specimen type for viral load (VL) monitoring. We assessed the programmatic utility of screening for antiretroviral (ARV) treatment failure (TF) at 5,000 and 1,000 copies/ml using DBS and dried plasma spots (DPS) with a commonly used VL assay, the Roche Cobas Ampliprep/Cobas TaqMan V.2.0 (CAP/CTM). Plasma, DBS, and DPS were prepared from 839 whole-blood specimens collected from patients on ART for ≥6 months at three public facilities in Namibia. Using the CAP/CTM test, VL were measured in plasma, DBS, and DPS, and the results were compared using the plasma VL as the reference standard. The clinical sensitivities, specificities, and positive (PPV) and negative predictive values (NPV) of DBS at ARV TF diagnostic thresholds of 5,000 copies/ml and 1,000 copies/ml were 0.99, 0.55, 0.33, and 0.99 and 0.99, 0.26, 0.29, and 0.99, respectively, and for DPS at TF diagnostic thresholds of 5,000 copies/ml and 1,000 copies/ml, they were 0.88, 0.98, 0.92, and 0.97 and 0.91, 0.96, 0.89, and 0.97, respectively. The prevalences of TF were overestimated in DBS by 33% and 57% at these two thresholds, respectively. A high rate of false-positive results would occur if the CAP/CTM with DBS were to be used to screen for ARV TF. WHO recommendations for DBS-based VL monitoring should be specific to the VL assay version and type. Despite the better performance of DPS, the programmatic utility for TF screening may be limited by requirements for processing the whole blood at the collection site.


PLOS ONE | 2017

ART attrition and risk factors among Option B+ patients in Haiti: A retrospective cohort study

Nancy Puttkammer; Jean Wysler Domercant; Michelle R. Adler; Krista Yuhas; Martine Pamphile Myrtil; Paul R. Young; Kesner Francois; Reynold Grand’Pierre; David W. Lowrance

Objectives In October 2012, the Haitian Ministry of Health endorsed the “Option B+” strategy to eliminate mother-to-child transmission of HIV and achieve HIV epidemic control. The objective of this paper is to assess and identify risk factors for attrition from the national ART program among Option B+ patients in the 12 months after ART initiation. Design This retrospective cohort study included patients newly initiating ART from October 2012-August 2013 at 68 ART sites covering 45% of all newly enrolled ART patients in all regions of Haiti. Methods With data from electronic medical records, we carried out descriptive analysis of sociodemographic, clinical, and pregnancy-related correlates of ART attrition, and used a modified Poisson regression approach to estimate relative risks in a multivariable model. Results There were 2,166 Option B+ patients who initiated ART, of whom 1,023 were not retained by 12 months (47.2%). One quarter (25.3%) dropped out within 3 months of ART initiation. Protective factors included older age, more advanced HIV disease progression, and any adherence counseling prior to ART initiation, while risk factors included starting ART late in gestation, starting ART within 7 days of HIV testing, and using an atypical ART regimen. Discussion Our study demonstrates early ART attrition among Option B+ patients and contributes evidence on the characteristics of women who are most at risk of attrition in Haiti. Our findings highlight the importance of targeted strategies to support retention among Option B+ patients.


PLOS ONE | 2012

2009 Pandemic Influenza A (H1N1) Virus Outbreak and Response – Rwanda, October, 2009–May, 2010

Justin Wane; Thierry Nyatanyi; Richard Nkunda; Joseph Rukelibuga; Zara Ahmed; Caitlin Biedron; Adeline Kabeja; Marie Aimée Muhimpundu; Alice Kabanda; Simon Antara; Olivier J. T. Briët; Jean Baptiste Koama; André Rusanganwa; Odette Mukabayire; Corine Karema; Pratima L. Raghunathan; David W. Lowrance

Background In October 2009, the first case of pandemic influenza A(H1N1)pdm09 (pH1N1) was confirmed in Kigali, Rwanda and countrywide dissemination occurred within several weeks. We describe clinical and epidemiological characteristics of this epidemic. Methods From October 2009 through May 2010, we undertook epidemiologic investigations and response to pH1N1. Respiratory specimens were collected from all patients meeting the WHO case definition for pH1N1, which were tested using CDC’s real time RT-PCR protocol at the Rwandan National Reference Laboratory (NRL). Following documented viral transmission in the community, testing focused on clinically severe and high-risk group suspect cases. Results From October 9, 2009 through May 31, 2010, NRL tested 2,045 specimens. In total, 26% (n = 532) of specimens tested influenza positive; of these 96% (n = 510) were influenza A and 4% (n = 22) were influenza B. Of cases testing influenza A positive, 96.8% (n = 494), 3% (n = 15), and 0.2% (n = 1) were A(H1N1)pdm09, Seasonal A(H3) and Seasonal A(non-subtyped), respectively. Among laboratory-confirmed cases, 263 (53.2%) were children <15 years and 275 (52%) were female. In total, 58 (12%) cases were hospitalized with mean duration of hospitalization of 5 days (Range: 2–15 days). All cases recovered and there were no deaths. Overall, 339 (68%) confirmed cases received oseltamivir in any setting. Among all positive cases, 26.9% (143/532) were among groups known to be at high risk of influenza-associated complications, including age <5 years 23% (122/532), asthma 0.8% (4/532), cardiac disease 1.5% (8/532), pregnancy 0.6% (3/532), diabetes mellitus 0.4% (2/532), and chronic malnutrition 0.8% (4/532). Conclusions Rwanda experienced a PH1N1 outbreak which was epidemiologically similar to PH1N1 outbreaks in the region. Unlike seasonal influenza, children <15 years were the most affected by pH1N1. Lessons learned from the outbreak response included the need to strengthen integrated disease surveillance, develop laboratory contingency plans, and evaluate the influenza sentinel surveillance system.

Collaboration


Dive into the David W. Lowrance's collaboration.

Top Co-Authors

Avatar

Jean Wysler Domercant

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Ray W. Shiraishi

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Barbara J. Marston

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

John P. Pitman

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Sridhar V. Basavaraju

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Jacques Boncy

Public health laboratory

View shared research outputs
Top Co-Authors

Avatar

Frantz Jean Louis

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Varough Deyde

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Anthony A. Marfin

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

David L. Fitter

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge